# An integrative ENCODE resource for cancer genomics

Jing Zhang\*, Donghoon Lee\*, Vineet Dhiman\*, Peng Jiang\*, William Meyerson, Matthew Ung, Shaoke Lou, Patrick Mcgillivray, Declan Clarke, Lucas Lochovsky, Lijia Ma, Grace Yu, Arif Harmanci, Mengting Gu, Koon-kiu Yan, Anurag Sethi, Qin Cao, Daifeng Wang, Gamze Gursoy, Jason Liu, Xiaotong Li, Michael Rutenberg Schoenberg, Joel Rozowsky, Lilly Reich, Juan Carlos Rivera-Mulia, Jie Xu, Jayanth Krishnan, Yanlin Feng, Jessica Adrian, James R Broach, Michael Bolt, Vishnu Dileep, Tingting Liu, Shenglin Mei, Takayo Sasaki, Claudia Trevilla-Garcia, Su Wang, Yanli Wang, Hongbo Yang, Chongzhi Zang, Feng Yue, David M. Gilbert, Michael Snyder, Kevin Yip, Chao Cheng, Robert Klein, X. Shirley Liu, Kevin White, Mark Gerstein

## Abstract

ENCODE comprises thousands of functional genomics data sets, related to many types of cancer; it is possible to tailor these into a targeted resource for interpreting cancer genomes. In particular, this resource can be used to measure the impact of non-coding mutations, constituting the bulk of the somatic variants. Moreover, by integrating advanced assays (e.g. STARR-seq) with many epigenetic features, we can make a more focused and refined genome annotation, increasing the power for detecting recurrent somatic mutations in cohorts. Second, ENCODE signal data, especially replication timing, allows constructing precise, cancer-matched models for background mutation rates considerably more accurate than previous models. Third, ENCODE data, incorporating new assays, such as Hi-C and RNA-binding protein assays, in addition to large-scale transcription-factor ChIP-seq, allows the construction of extensive regulatory networks. In some contexts, these networks reveal how connections "rewire" during oncogenesis, as well as how these changes relate to a stem-cell state. More generally, one can use ENCODE networks to prioritize regulators most associated with large-scale expression changes in cancer. Combining the networks with the refined annotations and background mutation models, one can develop a step-wise scheme for prioritizing non-coding mutations. Here, we show how this can be instantiated, and we perform a number of small-scale validations (i.e., luciferase assays and shRNA knockdowns) to demonstrate how the resource can highlight mutations with significant consequences in cancer.

[[JZ2MG: overall, I think the tense it confusing. In the into, we use present and conclusion we use past, need further clarification. What is your preference]]

## Introduction

The initial ENCODE release in 2012, along with other targeted functional genomic data, have motivated many integrative studies, some of which have focused on cancer genomes1-8. Specifically, functional genomics data have been used to investigate cancer in three ways. First, they enable researchers to evaluate the molecular functional impact of non-coding mutations -- the vast majority of variants in cancer genomes -- and to develop non-coding annotation “elements” (e.g., enhancers)7,9-12. Secondly, by incorporating genome-wide features (such as replication timing, methylation, and expression), functional genomics data sets can be used to estimate background mutation rates (BMR), which vary widely over the genome13-15. Precise BMR calibration enables us to accurately identify recurrently mutated annotation elements across cancer cohorts as candidate drivers16-18. Finally, ENCODE data and other genomic data sets have been used to link non-coding elements and organize them into regulatory networks, which have been used to gain a systems-level perspective on cancer19-21.

The new release of ENCODE data has a number of improvements over the last release, which was mainly focused on a limited number of cell types using RNA-seq, DNase-seq and ChIP-seq assays22. The new release has two new directions. First, it considerably broadened the number of cell types using the original assays. As such, the main ENCODE encyclopedia aims to utilize these to provide a general annotation resource applicable across many cell types. Second, ENCODE also expanded the number of advanced assays on several "top-tier" cell lines (e.g. STARR-seq, Hi-C, ChIA-PET, eCLIP and RAMPAGE). Many of these cell lines are associated with various types of cancer, including those of the blood, breast, liver, and lung (K562, MCF-7, HepG2, A549, see Fig. 1). Such rich functional assays and annotation resources in the new ENCODE release allow us to characterize these non-coding regions in depth and construct a customized ENCODE companion resource for Cancer genomics (which we dub EN-CODEC). This resource consists of a set of annotation files and codes available online (see suppl.). It comprises three main parts: background mutation rate models, compact annotations, and regulatory networks. We detail each of these parts below and provide illustrations of how they may be used to interpret cancer genomes after combining mutation and expression profiles from large cancer cohorts such as from the TCGA.

In particular, with a much wider selection of cell types, EN-CODEC provides substantially more functional genomics data that can be better matched to specific cancer types of interest, allowing a demonstrably improved background mutation rate estimation. In addition, for a number of well-known cancer cell types, it incorporates a large battery of data on histone marks with various more specialized assays. For example, in several model tumor types, we incorporate STARR-seq data, which directly measures the genome-wide enhancer activities, to accurately define core enhancers and used Hi-C and ChIA-PET data for accurate enhancer-gene linkage prediction. Consequently, relative to generic annotations, it constructs more compact annotations to maximize statistical power in the determination of mutationally burdened regions.

Finally, our resource significantly extends TF regulatory networks with comprehensive ChIP-seq coverage across cell-types and constructs additional networks from more recent assays such as eCLIP and Hi-C. For a few prominent cancer types (e.g. blood and liver cancer), these provide cell type specific networks in model tumor and normal cells, enabling direct measurement of potential regulatory changes in oncogenesis. Furthermore, a prevailing paradigm has held for decades that at least a subpopulation of tumor cells have the ability to self-renew, differentiate, and regenerate, in a manner that is similar to stem cells23. Hence, the top-tier cell line H1-hESC can serve as a valuable comparison when investigating the degree to which an oncogenic transformation moves towards or away from a stem-cell-like state. More generally, our network can better explain cancer specific expression patterns in tumors from cancer resources such as TCGA, and it also helps reveal key regulators that drive large-scale tumor-to-normal expression changes.

We combined the ENCODE networks with the compact annotation sets and mutational burdening analysis (from the enhanced background model) to propose a step-wise prioritizing scheme that highlights key mutations associated with cancer progression. We validated the functional impact of prioritized mutations and elements using focused experiments such as shRNA RNA-seq and luciferase assays. Such prioritization serves as an illustration of how the new EN-CODEC resource can immediately be used to help analyze existing cancer mutation data and cancer-associated gene expression.

## ENCODE data allows more accurate BMR estimation (for better cancer driver detection)

One of the most powerful ways of identifying key elements in cancer genomes is through mutation recurrence analysis to discover regions that harbor more mutations than expected. However, developing an expectation is non-trivial – the somatic mutation process can be influenced by numerous confounders (in the form of both external genomic factors and local sequence context factors), and these can result in false conclusions if not appropriately corrected16. Hence, we demonstrate how to integrate extensive ENCODE data to construct an accurate background mutation rate model in a wide range of cancer types.

We address this issue in a cancer-cohort-specific manner (see suppl.). Specifically, we separated the whole genome into bins (1Mb) and calculated bin-wise mutation counts. We used a negative binomial regression of the mutation counts against 475 genomic features across 229 cell types, including replication timing, chromatin accessibility, Hi-C, and expression profiles. In contrast to methods that use data from unmatched cell types, our approach automatically selects the most relevant features, thereby providing considerable improvements in BMR estimation (Fig. 2A). For example, using matched replication timing data in multiple cancer types significantly outperforms using just replication timing data from the unmatched HeLa-S3 cell line. Moreover, combining many different genomic features significantly improves the estimation accuracy upon this (Fig. 2B). The weightings of the features in the model are consistent with our expectations: for instance, for breast cancer, we observed elevated mutation rates in regions with the repressive mark H3K9me3 and a reduced mutation rate in regions with the activating, enhancer-associated mark H3K27ac13-15. Also, due to the correlated nature of genomic features across cell types, even approximate matching of a specific cancer type to a particular ENCODE cell line can still improve BMR estimation (see suppl.). Hence, our analyses may easily be extended to many cancer types.

## A focused, compact annotation increases power for detecting cancer drivers

A second advantage of leveraging ENCODE data in determining recurrently mutated regions is provided by maximizing the statistical power of burden tests. In traditional genomic analyses, a comprehensive set of annotations (usually covering as many base pairs as possible) is considered to be optimal. However, testing every possible nucleotide in the genome greatly reduces the statistical power for variant recurrence detection (see suppl.). Here, we aim to increase the power of burden tests by creating a focused, compact annotation for a given cell type.

First, for a single burden test on an individual genomic element (e.g., an enhancer), focusing on a smaller, "core" region, enriched for true functional impact, significantly improves detectability (see suppl.). Hence, we trimmed the conventional annotations to key "functional territories" by using the well-known small territories of TF-binding sites and the shapes of various genomic signals (e.g., the well-known double-hump of H3K27ac around enhancers, see suppl.).

Second, repeated burden tests on a large number of elements would be subject to a large multiple-testing penalty. Thus, we tried to restrict our annotation set to a minimum number of high-confidence elements. With a particular focus on enhancers, we started by searching for regions supported by multiple lines of evidence in the data-rich top-tier cell types. We developed a machine-learning algorithm to combine shapes of signal tracks from DNase-seq and a battery of up to 10 histone modification marks (see suppl.). Using a second algorithm, we then combined these predictions with our processing of the STARR-seq experiments (see suppl.). These experiments provide a direct, albeit noisy, readout of enhancer activity in specific cell types. Such an "ensemble" approach enables us to define a minimal list of enhancers with as few false-positives as possible. We also reconciled and cross-referenced our "compact annotation" with the main encyclopedia annotations (see suppl.).

## Linking genes to non-coding elements to create an extended gene annotation (for better cancer driver detection)

To increase statistical power, a final part of our "compact" annotation entails linking non-coding regulatory elements to protein-coding exons to form an extended gene region as a single test unit. Such a unified annotation enables joint evaluation of the mutational signals from distributed yet biologically connected genomic regions. Traditional methods for linking rely solely on the correlation of individual signals (e.g., between the activity of one histone mark at an enhancer and gene expression of neighboring genes), and these may result in inaccurate extended gene definitions. Here, we use direct experimental evidence on physical interactions from Hi-C and ChIA-PET experiments, combined with a machine learning algorithm that takes into consideration the wide variety of histone modification marks and gene expression to delineate accurate enhancer-target gene linkages.

By integrating our compact annotation sets, BMR estimates, and accurate extended gene definitions, we were able to obtain maximal power for detecting genomic regions (coding and non-coding) that are mutationally burdened. Fig. 2C illustrates the greater power in detecting mutationally burdened non-coding regions in several well-known cancer cohorts. For example, in the context of chronic lymphocytic leukemia (CLL), our analyses identified well-known highly mutated genes (such as TP53 and ATM) that have been reported from previous analyses. More importantly, the increased power provided by the extended-gene annotation allowed us to detect genes that would otherwise be missed by an exclusively coding analysis. An example of this is the well-known cancer gene BCL6, which may be associated with patient survival (Fig. 2D)24-26.

[[JZ2MG: expression of BCL6 is associated with CLL patient survival has been previously discovered. So it is not our own discovery! We can further weaken this sentence by the following suggested way]]

An example of this is the well-known cancer gene BCL6, and our analysis also confirmed previous reports of its association with patient survivals in CLL.

## Interpreting tumor expression profiles using ENCODE networks identifies key regulators in cancer

Building on the extended gene annotation, we provide detailed regulatory networks. Specifically, for TF networks, we incorporated both distal and proximal networks by linking TFs to genes, either directly by TF-promoter binding or indirectly via TF-enhancer-gene interactions in each cell type (see suppl.). We then pruned these networks to include only the strongest edges using a signal shape algorithm27 (see suppl.). In addition, we reconciled all our cell-type-specific networks to form a generalized pan-cancer network. Similarly, we also defined an RNA-binding protein (RBP) network from eCLIP experiments, which is an enhanced CLIP protocol that provides single-nucleotide resolution of the RBPs binding signatures28. By simplifying the generation of paired IgG and size-matched input controls, eCLIP improves specificity in the discovery of authentic binding sites. Compared to imputed networks derived from gene expression or motif analyses, our ENCODE TF and RBP networks provide much more accurate and experimentally based regulatory linkages between functional elements.

These ENCODE networks are useful for interpreting gene expression data from tumor samples. To make this possible, using a regression based scheme, we integrated 8,202 tumor expression profiles from TCGA to systematically search for the TFs and RBPs that most strongly drive tumor-specific expression (see suppl.). For each patient, we tested the degree to which a regulator's activity correlates with its target's tumor-to-normal expression changes. We then calculated the percentage of patients with these relationships in each cancer type and present the overall trends for key TFs and RBPs in Fig. 3A.

As expected, we found that the target genes of MYC are significantly up-regulated in numerous cancer types, consistent with its well-known role as an oncogenic TF29,30. We further validated MYC's regulatory effects using knockdown experiments in breast cancer (Fig. 3). Consistent with our predictions, the expression of MYC targets is significantly reduced after MYC knockdown in MCF-7 (Fig. 3B). We then used the regulatory network to investigate how MYC works with other TFs. We first looked at MYC's target genes co-regulated by a second TF, as shown in the triplets in Fig. 3C. In all cancer types, we found that the shared target genes' expressions are strongly positively correlated with MYC, while they showed only limited correlation with the second TF (as determined by partial correlation analysis, see suppl.). We further investigated the exact structure of these regulatory triplets. The most common one is the well-understood feed-forward loop (FFL). In this case, MYC regulates both another TF and a common target of both MYC and that TF (Fig. 3 C). Since MYC amplification is a major determinant of many cancers, understanding which TFs appear to further amplify its effects may yield insights for efforts aimed at MYC inhibition30. Most of the FFLs involve well-known MYC partners such as MAX and MXL1. However, we also discovered many involving NRF1. Upon further examination, we found that that the MYC-NRF1 FFL relationships were mostly coherent, i.e., "amplifying" in nature (Fig. 3C ii). We further studied these FFLs by organizing them into logic gates, in which two TFs act as inputs and the target gene expression represents the output31 (see suppl.). We show that most of these gates follow either an OR or MYC-always-dominant logic gate. Thus, the ENCODE regulatory network not only helps identify key regulators, but also illustrates how these may work in combination with other regulators.

We analyzed the RBP network similarly to the TF network, finding key regulators associated with cancer (see suppl.). For example, the ENCODE eCLIP profile for the RBP SUB1 has peaks enriched on the 3'UTR regions of genes, and the predicted targets of SUB1 were significantly up-regulated in many cancer types (Fig. 3C). As an RBP, SUB1 has not previously been associated with cancer, so we sought to validate its role. Knocking down of SUB1 in HepG2 cells significantly down-regulated its targets (Fig. 3D), and the decay rate of SUB1 targets is significantly lower than those of non-targets (see suppl.). Moreover, we found that up-regulation of SUB1 targets might indicates a poorer patient survival in some cancer types (Fig. 3D).

We further analyzed the overall TF regulatory network by systematically arranging it into a hierarchy (Fig. 4A). Here, TFs are placed at different levels such that those in the middle tend to regulate TFs below them and, in turn, are more regulated by TFs above them32 (see suppl.). In the hierarchy, we found that the top-layer TFs are not only enriched in cancer-associated genes but also more significantly drive differential gene expressions in model cell types.

**Cell-type specific regulatory networks highlight extensive rewiring events during oncogenesis**

For the top-tier cell types with numerous TF ChIP-seq experiments, our resource contains cell-type-specific regulatory networks, which enable in a model context, direct comparison with networks built from their paired normal cell types. To achieve the best paired normal, given the existing data, we construct a "composite normal" by reconciling multiple related normal cell types (see suppl.). Although the pairings are only approximate, many of them have previously been widely used in the literature (see suppl.). Furthermore, they leverage the extensive functional characterization assays in ENCODE to provide us with a unique opportunity to study the regulatory alterations in select cancers on a large scale.

In particular, in "tumor-normal pairs," we measured the signed, fractional number of edges changing (which we call the "rewiring index") to study how TF targets change in the oncogenic transformation. In Fig. 5A, we ranked TFs according to this index. In leukemia, well-known oncogenes (such as MYC and NRF1) were among the top edge gainers, while the well-known tumor suppressor IKZF1 is the most significant edge loser (Fig. 5A). Mutations in IKZF1 serve as a hallmark of various forms of high-risk leukemia33,34. We observed a similar rewiring trend using distal, proximal, and combined networks (details in supplement). This trend was also consistent across a number of cancers: highly rewired TFs such as BHLHE40, JUND, and MYC behaved similarly in lung, liver, and breast cancers (Fig. 5).

In addition to direct TF-to-gene connections, we also measured rewiring using a more complex gene-community model. Here, the targets within the regulatory network were characterized in terms of heterogeneous modules (so called "gene communities"), which come from multiple genes. Instead of directly measuring the changes in a TF's targets between tumor and normal cells, we determined the changes in its gene communities via a mixed-membership model (See suppl.). Similar patterns to the direct rewiring were observed using this model (Fig. 5A) and also in terms of a simpler co-binding approach (see suppl.).

We next tested whether the gain or loss events from normal-to-tumor transitions result in a network that is more or less similar to that in stem cells like H1-hESC. Interestingly, the gainer TF group tends to "rewire away" from the stem cell's regulatory network, while the loser group is more likely to rewire in such a way that it becomes more stem-like.

[[JZ2MG: you mentioned that the highlighted sentence is not clear. What mean is in that paper, it stated “only 10-20% disease causing mutations are mapped to TFBS, others are not known”. Hence, it supported our claim that the extensive rewiring events are not due to mutations disrupting TFBS]]

The majority of rewiring events were associated with noticeable gene expression and chromatin status changes, but not necessarily with mutation-induced motif loss or gain events (Fig. 5A). This is consistent with previous work that most non-coding risk variants are not well-explained by the current model35. For example, JUND is a top gainer in K562. The majority of its gained targets in tumor cells demonstrate higher gene expression, stronger active and weaker repressive histone modification mark signals, yet few of its binding sites are mutated. With a few notable exceptions (see suppl.), we found a similar trend for the rewiring events associated with JUND in liver cancer and, largely, for other factors in a variety of cancers. On a related note, we organized the cell-type-specific networks into hierarchies, as shown in Fig. 4B. Specifically, in blood cancer, the more mutationally burdened TFs sit at the bottom of the hierarchy, whereas the TFs more associated with driving cancer gene expression changes tend to be at the top.

## Step-wise prioritization schemes pinpoints deleterious SNVs in cancer

Summarizing the above, our companion resource consists of annotations in Fig. 1 and 6: (1) a BMR model with a matching procedure for the relevant functional genomics data and a list of regions with higher-than-expected mutational burdens in a diverse selection of cancers; (2) accurate and compactly defined enhancer and promotor annotation that is based on integrating many functional assays, including STARR-seq; (3) enhancer-target-gene linkages and extended gene neighborhoods that are obtained by integrating Hi-C and multi-histone-mark experiments; (4) tumor-normal differential expression, chromatin, and regulatory changes; (5) TF regulatory networks, both merged and cell-type specific, based on both distal and proximal regulation; (6) for each TF, its position in the network hierarchy and its rewiring status; and (7) an analogous but less-developed network for RBPs. All the resources mentioned above are available online through the ENCODE website as simple flat files and computer codes (see suppl.).

Collectively, these resources allow us to prioritize key genomic features associated with oncogenesis. Our prioritization scheme is schematized as a workflow in Fig. 6A. We first search for key regulators that are frequently rewired, located in network hubs, sit at the top of the hierarchy, or significantly drive expression changes in cancer. We then prioritize functional elements associated with these regulators, are highly mutated in tumors, or undergo large changes in gene expression, TF binding, or chromatin status. Finally, on a nucleotide level, by estimating their ability to disrupt or introduce specific binding sites, we pinpoint impactful SNVs.

## Small-scale validation experiments on the prioritization

To demonstrate the utility of the ENCODE resources, we instantiated our workflow in a few select cancers and experimentally validated the results. In particular, as described above, we subjected some key regulators, such as MYC and SUB1, to knockdown experiments to validate their regulatory effects (Fig. 3D). We also identified several candidate enhancers in noncoding regions associated with breast cancer and validated their ability to influence transcription using luciferase assays in MCF-7. Finally, we selected key SNVs, based on mutation recurrence in breast-cancer cohorts within these enhancers that are important for controlling gene expression. Of the eight motif-disrupting SNVs that we tested, six exhibited consistent up- or down-regulation relative to the wild-type in multiple biological replicates.

One particularly interesting example, illustrating the value of ENCODE data integration, is in an intronic region of CDH26 in chromosome 20 (Fig. 6C). The signal shapes for both histone modification and chromatin accessibility (DNase-seq) data indicate its active regulatory role as an enhancer in MCF-7. This was further confirmed by STARR-seq (Fig. 6D). Hi-C and ChIA-PET linkages indicated that the region is within a topologically associated domain and validated a regulatory connection to the downstream breast-cancer-associated gene SYCP236. We further observed strong binding of many TFs in this region in MCF-7. Motif analysis predicts that the particular mutation from a breast cancer patient significantly disrupts the binding affinity of several TFs, such as FOSL2, in this region (Fig. 6D). Luciferase assays demonstrated that this mutation introduces a 3.6-fold reduction in expression relative to the wild-type, indicating a strong repressive effect on enhancer functionality.

## Conclusion

This study highlights the value of ENCODE data as an aid to interpreting cancer genomes. It presents the EN-CODEC companion resource, which tailors the ENCODE annotation to cancer. It comprises three parts: 1) cancer-specific BMR models with significantly increased accuracy; 2) compact annotations that are suitable for recurrent-mutation detection by maximizing statistical power; and 3) various regulatory networks and hierarchies for both pan-cancer and cancer-specific studies.

One key caveat in our resource concerns the model cell type specific networks. Their utility for cancer is based on pairing them to particular cancer types. Although the representative tumor and normal cell types and their pairings are approximate, we feel that the networks provide the best current view on the regulatory changes in oncogenesis. No other system has this scale of TF-chip data. Moreover, the heterogeneous nature of cancer means that even tumor cells from a given patient usually show distinct molecular, morphological, and genetic profiles37. It will be difficult to obtain a "perfect" match even from real tumor and normal tissues taken from a single patient.

In general, our study underscores the value of large-scale data integration, and we note that expanding the scale of our approach in a number of dimensions is straightforward. For example, we observed increased accuracy in BMR estimation with additional genomic features; we expect that this accuracy will increase further still with more features. We successfully formed compact annotations and regulatory networks for model systems already replete with advanced functional assays like eCLIP and STARR-seq; our methods can be readily extended to other model systems when they are similarly assayed in the future. Given the rewiring formalism presented here, it should be straightforward to expand the analysis to greater numbers of TFs. (In fact, the re-wiring formalism provides a way of selecting candidate TFs and cell types.) This will give us a greater sense of which regulators tend to be affected by extensive chromatin changes and thus help prioritize research efforts in cancer.

Finally, we demonstrated the utility of our resource for assisting in the detection of potential cancer drivers in limited publically available cohorts; we anticipate that linking it with the large cohorts currently being assembled (e.g., PCAWG, [pancaner.info](http://pancaner.info/)) will more fully utilize both resources and provide even greater value.

## Reference

1. Gerstein, M.B. *et al.* Architecture of the human regulatory network derived from ENCODE data. *Nature* **489**, 91-100 (2012).

2. Cai, Q. *et al.* Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. *Nat Genet* **46**, 886-90 (2014).

3. Jager, R. *et al.* Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. *Nat Commun* **6**, 6178 (2015).

4. Fredriksson, N.J., Ny, L., Nilsson, J.A. & Larsson, E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. *Nat Genet* **46**, 1258-63 (2014).

5. Cancer Genome Atlas Research, N. *et al.* Integrated genomic and molecular characterization of cervical cancer. *Nature* **543**, 378-384 (2017).

6. Hoadley, K.A. *et al.* Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* **158**, 929-44 (2014).

7. Khurana, E. *et al.* Integrative annotation of variants from 1092 humans: application to cancer genomics. *Science* **342**, 1235587 (2013).

8. Torchia, J. *et al.* Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. *Cancer Cell* **30**, 891-908 (2016).

9. Hoffman, M.M. *et al.* Integrative annotation of chromatin elements from ENCODE data. *Nucleic Acids Res* **41**, 827-41 (2013).

10. Boyle, A.P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res* **22**, 1790-7 (2012).

11. Rheinbay, E. *et al.* Recurrent and functional regulatory mutations in breast cancer. *Nature* **547**, 55-60 (2017).

12. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis of noncoding regulatory mutations in cancer. *Nat Genet* **46**, 1160-5 (2014).

13. Makova, K.D. & Hardison, R.C. The effects of chromatin organization on variation in mutation rates in the genome. *Nat Rev Genet* **16**, 213-23 (2015).

14. Polak, P. *et al.* Cell-of-origin chromatin organization shapes the mutational landscape of cancer. *Nature* **518**, 360-4 (2015).

15. Schuster-Bockler, B. & Lehner, B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. *Nature* **488**, 504-7 (2012).

16. Lawrence, M.S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **499**, 214-8 (2013).

17. Melton, C., Reuter, J.A., Spacek, D.V. & Snyder, M. Recurrent somatic mutations in regulatory regions of human cancer genomes. *Nat Genet* **47**, 710-6 (2015).

18. Lochovsky, L., Zhang, J., Fu, Y., Khurana, E. & Gerstein, M. LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. *Nucleic Acids Res* **43**, 8123-34 (2015).

19. Hofree, M., Shen, J.P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. *Nat Methods* **10**, 1108-15 (2013).

20. Jacobsen, A. *et al.* Analysis of microRNA-target interactions across diverse cancer types. *Nat Struct Mol Biol* **20**, 1325-32 (2013).

21. Mutation, C. & Pathway Analysis working group of the International Cancer Genome, C. Pathway and network analysis of cancer genomes. *Nat Methods* **12**, 615-21 (2015).

22. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57-74 (2012).

23. O'Connor, M.L. *et al.* Cancer stem cells: A contentious hypothesis now moving forward. *Cancer Lett* **344**, 180-7 (2014).

24. Jantus Lewintre, E. *et al.* BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia. *Leuk Lymphoma* **50**, 773-80 (2009).

25. Cardenas, M.G. *et al.* The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. *Clin Cancer Res* **23**, 885-893 (2017).

26. Capello, D. *et al.* Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. *Leukemia* **14**, 811-5 (2000).

27. Cheng, C., Min, R. & Gerstein, M. TIP: a probabilistic method for identifying transcription factor target genes from ChIP-seq binding profiles. *Bioinformatics* **27**, 3221-7 (2011).

28. Van Nostrand, E.L. *et al.* Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). *Nat Methods* **13**, 508-14 (2016).

29. Dang, C.V. MYC on the path to cancer. *Cell* **149**, 22-35 (2012).

30. McKeown, M.R. & Bradner, J.E. Therapeutic strategies to inhibit MYC. *Cold Spring Harb Perspect Med* **4**(2014).

31. Wang, D. *et al.* Loregic: a method to characterize the cooperative logic of regulatory factors. *PLoS Comput Biol* **11**, e1004132 (2015).

32. Cheng, C. *et al.* An approach for determining and measuring network hierarchy applied to comparing the phosphorylome and the regulome. *Genome Biol* **16**, 63 (2015).

33. de Rooij, J.D. *et al.* Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia. *Haematologica* **100**, 1151-9 (2015).

34. Boer, J.M. *et al.* Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. *Leukemia* **30**, 32-8 (2016).

35. Farh, K.K. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* **518**, 337-43 (2015).

36. Masterson, L. *et al.* Deregulation of SYCP2 predicts early stage human papillomavirus-positive oropharyngeal carcinoma: A prospective whole transcriptome analysis. *Cancer Sci* **106**, 1568-75 (2015).

37. Meacham, C.E. & Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. *Nature* **501**, 328-37 (2013).